Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation

PRINCETON, N.J.--(BUSINESS WIRE)--May 25, 2023-- https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bms.com&esheet=53406920&newsitemid=20230524005933&lan=en-US&anchor=Bristol+Myers+Squibb&index=1&md5=3438b293ce428cbb31e108cf9d486d27 (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen), today announced that all three [...]